About Translumina
Translumina is a Healthcare company based in Hechingen (Germany) founded in 2010. The company has 363 employees. Translumina has completed 2 acquisitions, including Blue Medical and Lamed. Its chief executive, as recorded, is Paritosh Arora. Its Indian entity Translumina Therapeutics Llp reported revenue of ₹376 Cr. Translumina offers products and services including Drug Eluting Stents, Drug Eluting Balloons, PTCA Balloons, and Coronary Balloons. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices.
Company details
Translumina was founded in 2010 and is based in Hechingen, Germany. Operations focus on the cardiovascular sector, where drug-eluting stents, drug-eluting balloons, coronary balloons, and vascular accessories are produced. Advanced manufacturing facilities are maintained to meet international standards. Innovative technologies for cardiovascular interventions are developed and supplied through these processes.
- Headquarters Hechingen, Germany
- Employees 363
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website translumina.com
- Social LinkedIn X Facebook Instagram YouTube
- Legal Name Translumina Therapeutics Llp
- Date of Incorporation 01 Dec, 2009
- Jurisdiction New Delhi, Delhi, India
- Indian entity revenue₹376 Cr
FY 2023 · +39% YoY
- Indian entity EBITDA₹2.29 Cr
FY 2023 · 1% margin
- InvestorsEverstone Capital
& 1 more
- Employee Count363
- Investments & AcquisitionsBlue Medical
& 1 more
Associated legal entities of Translumina
Translumina is associated with 3 registered companies on The Company Check; the primary company is Translumina Therapeutics Llp. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Translumina Therapeutics Llp CIN AAA-0435 | Converted And Dissolved | 01 Dec 2009 | New Delhi, Delhi | ₹376 Cr | 363 | 6 | View details |
| Integris Health Private Limited CIN U85110DL2008PTC177230 | Active | 25 Apr 2008 | New Delhi, Delhi, India | View details | |||
| Integris Medtech Limited CIN U85110DL2008PLC177230 | Active | 25 Apr 2008 | New Delhi, Delhi | ₹1,960 Cr | 12 | View details |
Products & Services of Translumina
Translumina offers a comprehensive portfolio of products and services, including Drug Eluting Stents, Drug Eluting Balloons, PTCA Balloons, and Coronary Balloons.
Devices that release drugs to prevent artery re-narrowing in treatments
Balloons delivering drugs during vascular procedures for better outcomes
Balloons used in angioplasty to open blocked coronary arteries
Specialized balloons for enhancing cardiovascular interventions effectively
Apps and channels of Translumina
its YouTube channel Translumina Therapeutics has 1.47K subscribers and 30 videos.
Videos from Translumina
The most watched videos on Translumina's YouTube channel, Translumina Therapeutics (1.47K subscribers). Click a video to play it here.
More on Translumina Therapeutics.
Funding Insights of Translumina
- Total Rounds 2
- Investors Count 2
All 2 funding rounds of Translumina with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2024 | Seed | – | – | ||
| Aug 2019 | Seed | – | Everstone Capital | – |
2 investors in total: 2 institutional.
Investors in Translumina
Translumina has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Everstone Capital and India SME Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity fund focused on multiple sectors | 2019 | indiasmeinvestments.com | Mumbai, India | |
Private equity investments in mid-market businesses linked to India and Southeast Asia. | 2006 | everstonecapital.com | Singapore, Singapore |
Investor details for Translumina
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Translumina Therapeutics Llp (Translumina)
Translumina Therapeutics Llp is the primary company behind Translumina. The boards of the 2 registered companies of Translumina currently have 13 directors; the longest-serving is Punita Sharma, appointed in 2009. 13 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Punita Sharma DIN 00821812 | Designated Partner | 01 Dec 2009 | 16 yrs 11 mo | Translumina Therapeutics Llp, Integris Medtech Limited |
| Gurmit Singh Chugh DIN 00821824 | Partner | 17 May 2019 | 7 yrs 5 mo | Translumina Therapeutics Llp, Integris Medtech Limited |
| Vishal Sharma DIN 01599024 | Designated Partner | 11 Mar 2020 | 6 yrs 8 mo | Translumina Therapeutics Llp |
| Avnish Mehra DIN 02221045 | Partner | 11 Mar 2020 | 6 yrs 8 mo | Translumina Therapeutics Llp, Integris Medtech Limited |
| Indranil Mukherjee DIN 06692898 | Designated Partner | 15 Mar 2024 | 2 yrs 7 mo | Translumina Therapeutics Llp |
| Vishal Omprakash Goenka DIN 10084887 | Designated Partner | 15 Mar 2024 | 2 yrs 7 mo | Translumina Therapeutics Llp, Integris Medtech Limited |
| Arjun Oberoi DIN 08277173 | Nominee Director | 21 Jul 2025 | 1 yr 3 mo | Integris Medtech Limited |
| Rajani Kesari DIN 02384170 | Director | 01 Aug 2025 | 1 yr 3 mo | Integris Medtech Limited |
| Ramesh Subrahmanian DIN 02933019 | Director | 01 Aug 2025 | 1 yr 3 mo | Integris Medtech Limited |
| Hemant Sultania DIN 00472577 | CFO | 25 Aug 2025 | 1 yr 2 mo | Integris Medtech Limited |
| Probir Das DIN 06588579 | CEO | 25 Aug 2025 | 1 yr 2 mo | Integris Medtech Limited |
| Annaswamy Vaidheesh DIN 01444303 | Director | 26 Aug 2025 | 1 yr 2 mo | Integris Medtech Limited |
| Darpan Batra DIN 08823019 | Company Secretary | 26 Sep 2025 | 1 yr 1 mo | Integris Medtech Limited |
People of Translumina
2 people are tracked at Translumina (2 in leadership); the tracked headcount is 363.
| Name | Role | Group |
|---|---|---|
Paritosh Arora | CEO & MD | Leadership |
| Managing Director | Leadership |
Complete people profiles for Translumina
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Translumina
Figures of Translumina Therapeutics Llp, the primary company behind Translumina, for FY 2023. Revenue was ₹376 Cr (+39% year on year). EBITDA was ₹2.29 Cr (1% margin). Revenue has grown at a compounded annual rate of +25% over three years and +21% over five years.
- ₹376 CrRevenue · FY 2023 · +39% YoY
- ₹2.29 CrEBITDA · 1% margin
- 363Employees (provident fund records)
- +25%Revenue CAGR, 3 years
- +21%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Translumina Therapeutics Llp are on its company page.
Detailed financial statements for Translumina
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Translumina
Translumina has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Blue Medical and Lamed.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Develops stents and catheters | bluemedical.com | Helmond, Netherlands | 1998 | Jun 2023 | •••• | |
Endovascular solutions for thoracic aortic dissections are developed. | lamed.de | Oberhaching, Germany | 1989 | Jun 2023 | •••• |
Complete acquisition details for Translumina
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Translumina
5 dated milestones of Translumina across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Translumina is founded.
- Funding First funding round.
- Acquisition Acquires Lamed.
- Acquisition Acquires Blue Medical.
- Funding Latest funding round, Seed,.
Web traffic of Translumina
The website of Translumina (translumina.com) receives about 5.2K visits a month.
- Monthly visits5.2K
▼ 3.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Translumina
Complete news archive for Translumina
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Translumina
Translumina was founded in 2010 and raised its 1st funding round 9 years after it was founded.
Translumina is headquartered in Hechingen, Germany. It is registered at Hechingen, Baden-wurttemberg, Germany.
Paritosh Arora is the CEO of Translumina, as recorded in our data.
Translumina has 363 employees.
The primary company behind Translumina, Translumina Therapeutics Llp, reported revenue of ₹376 Cr for FY 2023, up 39% year on year.
Translumina was founded in 2010 and is based in Hechingen, Germany. Operations focus on the cardiovascular sector, where drug-eluting stents, drug-eluting balloons, coronary balloons, and vascular accessories are produced. Advanced manufacturing facilities are maintained to meet international standards. Innovative technologies for cardiovascular interventions are developed and supplied through these processes.
Translumina offers Drug Eluting Stents, Drug Eluting Balloons, PTCA Balloons, and Coronary Balloons.
Translumina has made 2 acquisitions, including Blue Medical, and Lamed.
Translumina has 2 investors. Key investors include Everstone Capital, and India SME Investments.
Translumina is associated with 2 legal entities: Translumina Therapeutics Llp, Integris Medtech Limited.
The legal entities of Translumina currently have 13 directors, including Vishal Sharma, Indranil Mukherjee, Gurmit Singh Chugh and others.